株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

カルシトニン遺伝子関連ペプチド1受容体:パイプライン製品の分析

Calcitonin Gene Related Peptide Type 1 Receptor - Pipeline Review, H2 2019

発行 Global Markets Direct 商品コード 369086
出版日 ページ情報 英文 65 Pages
即納可能
価格
本日の銀行送金レート: 1USD=111.33円で換算しております。
Back to Top
カルシトニン遺伝子関連ペプチド1受容体:パイプライン製品の分析 Calcitonin Gene Related Peptide Type 1 Receptor - Pipeline Review, H2 2019
出版日: 2019年12月27日 ページ情報: 英文 65 Pages
概要

当レポートでは、カルシトニン遺伝子関連ペプチド1受容体を標的とした治療薬開発パイプラインの現況と最新アップデートによる各開発段階の比較分析、企業や研究機関によって開発中の治療薬、治療薬の評価、後期段階および中止されたプロジェクトに関する情報などを最新のニュースや発表も交えて提供しています。

イントロダクション

  • 調査範囲

カルシトニン遺伝子関連ペプチド1受容体 概要

治療薬の開発

  • 開発中の製品:開発段階別
  • 開発中の製品:治療領域別
  • 開発中の製品:症状別

パイプライン製品の概況

  • 後期段階の製品
  • 初期段階の製品

企業で開発中の製品

治療薬の評価

  • 単剤/併用治療薬の場合
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

治療薬開発に従事している企業

  • Allergan Plc
  • Amgen Inc.
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • Merck & Co., Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Vertex Pharmaceuticals Incorporated

薬剤プロファイル

休止中のプロジェクト

開発が中止された製品

主なニュースおよびプレスリリース

付録

図表

図表

List of Tables

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Indication, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Pipeline by Allergan Plc, H2 2019
  • Pipeline by Amgen Inc, H2 2019
  • Pipeline by Biohaven Pharmaceutical Holding Company Ltd, H2 2019
  • Pipeline by Merck & Co Inc, H2 2019
  • Pipeline by Sosei Heptares, H2 2019
  • Dormant Projects, H2 2019
  • Discontinued Products, H2 2019

List of Figures

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Top 10 Indications, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Routes of Administration, H2 2019
  • Number of Products by Stage and Routes of Administration, H2 2019
  • Number of Products by Molecule Types, H2 2019
  • Number of Products by Stage and Molecule Types, H2 2019
目次
Product Code: GMDHC2175TDB

Summary

Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) - Calcitonin receptor-like (CALCRL) also known as the calcitonin receptor-like receptor (CRLR) is a G protein-coupled receptor. The association of CALCRL with different RAMP proteins produces different receptors which with RAMP1 acts as a receptor for calcitonin-gene-related peptide, with RAMP2 acts as a receptor for adrenomedullin-1and with RAMP3 act as a receptor for adrenomedullin-2. It plays an important role in treatment of migraine.

Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) pipeline Target constitutes close to 6 molecules.The molecules developed by companies in Pre-Registration, Phase III and Preclinical stages are 1, 3 and 2 respectively. Report covers products from therapy areas Central Nervous System which include indications Migraine, Trigeminal Neuralgia (Tic Douloureux) and Tension -Type Headache.

The latest report Calcitonin Gene Related Peptide Type 1 Receptor - Pipeline Review, H2 2019, outlays comprehensive information on the Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL)
  • The report reviews Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) - Overview
  • Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) - Companies Involved in Therapeutics Development
  • Allergan Plc
  • Amgen Inc
  • Biohaven Pharmaceutical Holding Company Ltd
  • Merck & Co Inc
  • Sosei Heptares
  • Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) - Drug Profiles
  • atogepant - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • BHV-3500 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • erenumab - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • HTL-0022562 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • MK-8825 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • rimegepant - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) - Dormant Products
  • Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) - Discontinued Products
  • Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) - Product Development Milestones
  • Featured News & Press Releases
  • Dec 18, 2019: Biohaven reports positive data from migraine trial of vazegepant
  • Oct 31, 2019: Cycle Pharmaceuticals and Catalent partner to develop treatments for rare diseases using Zydis ODT Technology
  • Sep 27, 2019: NICE rejects Novartis' migraine drug Aimovig over data concerns
  • Sep 12, 2019: Biohaven closes enrolment in vazegepant's Phase II/III study
  • Sep 09, 2019: Biohaven presents data demonstrating reduction in Migraine-related disability and improvement in patient reported outcomes after oral treatment with Rimegepant at The International Headache Conference Late Breaking Session
  • Aug 08, 2019: Biohaven completes patient enrolment in rimegepant trial for migraine
  • Jul 15, 2019: Biohaven's positive phase 3 trial of Rimegepant Zydis orally dissolving tablet for acute treatment of migraine published in The Lancet
  • Jul 11, 2019: Rimegepant shows positive result as migraine drug in Phase III trial
  • Jul 11, 2019: Biohaven showcases positive data on Rimegepant, oral CGRP receptor antagonist, with 16 presentations at 2019 American Headache Society (AHS) Annual Scientific Meeting demonstrating efficacy in multiple patient types and long-term safety
  • Jul 10, 2019: New antibody treatment provides little relief for high-frequency migraine patients
  • Jul 09, 2019: Allergan provides update on atogepant at the 2019 American Headache Society Annual Meeting
  • Jul 03, 2019: Biohaven starts enrolment in rimegepant's trigeminal neuralgia trial
  • Jul 02, 2019: Novartis' Aimovig yields positive data in open label period
  • Jul 01, 2019: Novartis data show Aimovig cuts acute migraine medication days by half in patients who failed prior preventive therapies
  • Jun 24, 2019: Biohaven to present 16 abstracts at 2019 American Headache Society (AHS) Annual Scientific Meeting highlighting new data with Rimegepant, oral CGRP receptor antagonist
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer
Back to Top